{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:24:01Z","timestamp":1787743441130,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75776-1","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:46:38Z","timestamp":1784803598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular profiling and access to treatment for rare cancers in Europe"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8786-0645","authenticated-orcid":false,"given":"M.","family":"Morfouace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0479-4074","authenticated-orcid":false,"given":"F.","family":"Hoogstoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-1548","authenticated-orcid":false,"given":"N.","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-8643","authenticated-orcid":false,"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Peron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brasiuniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7576-6938","authenticated-orcid":false,"given":"A.","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gennigens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gorlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-2132","authenticated-orcid":false,"given":"G.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-7910","authenticated-orcid":false,"given":"M.","family":"Gamulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Idbaih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WTA","family":"Van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"J. Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"75776_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet\u2014a population-based study.  Lancet Oncol. 18, 1022\u20131039 (2017).","journal-title":"Lancet Oncol."},{"key":"75776_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103013","volume":"140","author":"WTA Van Der Graaf","year":"2025","unstructured":"Van Der Graaf, W. T. A. et al. Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action. Cancer Treat. Rev. 140, 103013 (2025).","journal-title":"Cancer Treat. Rev."},{"key":"75776_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ygyno.2020.02.012","volume":"157","author":"C Lenck","year":"2020","unstructured":"Lenck, C. et al. The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study. Gynecol. Oncol. 157, 78\u201384 (2020).","journal-title":"Gynecol. Oncol."},{"key":"75776_CR4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/cancers16071365","volume":"16","author":"F Gouin","year":"2024","unstructured":"Gouin, F. et al. Improved metastatic-free survival after systematic re-excision following complete macroscopic unplanned excision of limb or trunk soft tissue sarcoma. Cancers 16, 1365 (2024).","journal-title":"Cancers"},{"key":"75776_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.annonc.2024.01.001","volume":"35","author":"JY Blay","year":"2024","unstructured":"Blay, J. Y. et al. Improved nationwide survival of sarcoma patients with a network of reference centers. Ann. Oncol. 35, 351\u2013363 (2024).","journal-title":"Ann. Oncol."},{"key":"75776_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/annonc\/mdz124","volume":"30","author":"J-Y Blay","year":"2019","unstructured":"Blay, J.-Y. et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann. Oncol. 30, 1143\u20131153 (2019).","journal-title":"Ann. Oncol."},{"key":"75776_CR7","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1093\/annonc\/mdx484","volume":"28","author":"J-Y Blay","year":"2017","unstructured":"Blay, J.-Y. et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann. Oncol. 28, 2852\u20132859 (2017).","journal-title":"Ann. Oncol."},{"key":"75776_CR8","doi-asserted-by":"crossref","unstructured":"Othus, M. et al. Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without prior anti-PD-1\/L1 exposure (NCI\/SWOG S1609). JCO Oncol. Adv. 2, e2500110 (2025).","DOI":"10.1200\/OA-25-00110"},{"key":"75776_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer, A. et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 228\u2013246 (2023).","journal-title":"Ann. Oncol."},{"key":"75776_CR10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","volume":"36","author":"CB Westphalen","year":"2025","unstructured":"Westphalen, C. B. et al. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Ann. Oncol. 36, 614\u2013625 (2025).","journal-title":"Ann. Oncol."},{"key":"75776_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","volume":"35","author":"CB Westphalen","year":"2024","unstructured":"Westphalen, C. B. et al. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ann. Oncol. 35, 936\u2013953 (2024).","journal-title":"Ann. Oncol."},{"key":"75776_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 35, 588\u2013606 (2024).","journal-title":"Ann. Oncol."},{"key":"75776_CR13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"75776_CR14","doi-asserted-by":"publisher","first-page":"103928","DOI":"10.1016\/j.critrevonc.2023.103928","volume":"183","author":"S Nakhaei-Rad","year":"2023","unstructured":"Nakhaei-Rad, S., Soleimani, Z., Vahedi, S. & Gorjinia, Z. Testicular germ cell tumors: genomic alternations and RAS-dependent signaling. Crit. Rev. Oncol.\/Hematol. 183, 103928 (2023).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"75776_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53193-6","volume":"15","author":"M N\u00ed Leathlobhair","year":"2024","unstructured":"N\u00ed Leathlobhair, M. et al. Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project. Nat. Commun. 15, 9247 (2024).","journal-title":"Nat. Commun."},{"key":"75776_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/cancers13020220","volume":"13","author":"K Hodroj","year":"2021","unstructured":"Hodroj, K. et al. Molecular characterization of ovarian yolk sac tumor (OYST). Cancers 13, 220 (2021).","journal-title":"Cancers"},{"key":"75776_CR17","doi-asserted-by":"crossref","unstructured":"Moore, J. A. et al. Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-Ribose) polymerase inhibitor response. JCO Precis. Oncol. 7, e2300093 (2023).","DOI":"10.1200\/PO.23.00093"},{"key":"75776_CR18","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-24-1225","volume":"30","author":"DL Richardson","year":"2024","unstructured":"Richardson, D. L. et al. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a Scar-based HRD signature in real-world practice. Clin. Cancer Res. 30, 4644\u20134653 (2024).","journal-title":"Clin. Cancer Res."},{"key":"75776_CR19","doi-asserted-by":"crossref","unstructured":"Anbil, S. et al. LODESTAR: a single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes. JCO Precis. Oncol. 9, e2500090 (2025).","DOI":"10.1200\/PO-25-00090"},{"key":"75776_CR20","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41591-025-03926-x","volume":"31","author":"R Casolino","year":"2025","unstructured":"Casolino, R. et al. The WHO global landscape of cancer clinical trials. Nat. Med. 31, 2901\u20132912 (2025).","journal-title":"Nat. Med."},{"key":"75776_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105287","volume":"10","author":"P Van Der Laan","year":"2025","unstructured":"Van Der Laan, P. et al. The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma. ESMO Open 10, 105287 (2025).","journal-title":"ESMO Open"},{"key":"75776_CR22","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1158\/1538-7445.AM2025-7470","volume":"85","author":"M Morfouace","year":"2025","unstructured":"Morfouace, M. et al. Abstract 7470: Extensive genome sequencing on tissue vs large ctDNA panel: what clinical impact? Cancer Res. 85, 7470\u20137470 (2025).","journal-title":"Cancer Res."},{"key":"75776_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. CompreheNsive Characterization Of Cancer Driver Genes And Mutations. Cell 173, 371\u2013385.e18 (2018).","journal-title":"Cell"},{"key":"75776_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110100","volume":"37","author":"Y Shah","year":"2021","unstructured":"Shah, Y. et al. Pan-cancer analysis reveals molecular patterns associated with age. Cell Rep. 37, 110100 (2021).","journal-title":"Cell Rep."},{"key":"75776_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105856","volume":"10","author":"E Colombo","year":"2025","unstructured":"Colombo, E. et al. Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study. ESMO Open 10, 105856 (2025).","journal-title":"ESMO Open"},{"key":"75776_CR26","doi-asserted-by":"publisher","first-page":"16355","DOI":"10.1007\/s00432-023-05365-y","volume":"149","author":"S Rae","year":"2023","unstructured":"Rae, S. et al. Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders. J. Cancer Res. Clin. Oncol. 149, 16355\u201316363 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"75776_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","volume":"34","author":"A Bayle","year":"2023","unstructured":"Bayle, A. et al. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. Ann. Oncol. 34, 389\u2013396 (2023).","journal-title":"Ann. Oncol."},{"key":"75776_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41591-025-03613-x","volume":"31","author":"O Tr\u00e9dan","year":"2025","unstructured":"Tr\u00e9dan, O. et al. Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial. Nat. Med 31, 1502\u20131508 (2025).","journal-title":"Nat. Med"},{"key":"75776_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112959","volume":"191","author":"M Padovan","year":"2023","unstructured":"Padovan, M. et al. Actionable molecular alterations in newly diagnosed and recurrent IDH1\/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis. Eur. J. Cancer 191, 112959 (2023).","journal-title":"Eur. J. Cancer"},{"key":"75776_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104112","volume":"10","author":"K Verkerk","year":"2025","unstructured":"Verkerk, K. et al. The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP). ESMO Open 10, 104112 (2025).","journal-title":"ESMO Open"},{"key":"75776_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/1651-226X.2024.32745","volume":"63","author":"L Verlingue","year":"2024","unstructured":"Verlingue, L. et al. The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST. AO 63, 411\u2013417 (2024).","journal-title":"AO"},{"key":"75776_CR32","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","volume":"31","author":"P Marchetti","year":"2025","unstructured":"Marchetti, P. et al. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial. Nat. Med 31, 3514\u20133523 (2025).","journal-title":"Nat. Med"},{"key":"75776_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100861","volume":"39","author":"J-Y Blay","year":"2024","unstructured":"Blay, J.-Y. et al. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN.  Lancet Reg Health Eur. 39, 100861 (2024).","journal-title":"Lancet Reg Health Eur."},{"key":"75776_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaoncol.2021.5153","volume":"8","author":"S Brown","year":"2022","unstructured":"Brown, S. et al. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. JAMA Oncol. 8, 287 (2022).","journal-title":"JAMA Oncol."},{"key":"75776_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pst.2257","volume":"22","author":"Y Jin","year":"2023","unstructured":"Jin, Y., Ton, T. G. N., Incerti, D. & Hu, S. Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R. Pharm. Stat. 22, 194\u2013204 (2023).","journal-title":"Pharm. Stat."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75776-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:03:53Z","timestamp":1787742233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75776-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75776"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75776-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fanny Hoogstoel reports financial support was provided by EORTC Cancer Research Fund. Richard Huang reports a relationship with Foundation Medicine Inc that includes employment. Winette Van der Graaf reports a relationship with Eli Lilly and Company that includes funding grants. All remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8981"}}